☆ 4.8 Article

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

LANCET (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Javed Butler et al.

Summary: This study evaluated the impact of Empagliflozin on health-related quality of life in patients with heart failure and preserved ejection fraction. The results showed that Empagliflozin reduced the risk of major heart failure outcomes and improved health-related quality of life. The effects were consistent across different levels of baseline health status.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Javed Butler et al.

Summary: The impact of empagliflozin on heart failure outcomes was consistent and clinically meaningful in patients with ejection fractions <25% to <65%, but attenuated in those with ejection fraction >= 65%.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction

Muthiah Vaduganathan et al.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions

Stefan D. Anker et al.

Summary: This study analyzed the data from EMPEROR-Preserved using the endpoint definitions from the DELIVER trial. The findings showed that the effect of empagliflozin became statistically significant in patients with EF <60% when using the DELIVER definition.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure replaces previous guidelines and aims to provide patient-centric recommendations for clinicians based on contemporary evidence, with the goal of improving quality of care and aligning with patients' interests.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

John A. Spertus et al.

Summary: Large traditional clinical trials have shown that sodium-glucose co-transporter 2 inhibitors can improve symptoms in heart failure patients. In a new trial conducted remotely (CHIEF-HF trial), canagliflozin was found to significantly improve symptoms in heart failure patients, regardless of ejection fraction or diabetes status.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial

Milton Packer et al.

Summary: Empagliflozin reduces the risk and total number of worsening heart failure events in patients with heart failure and reduced ejection fraction, with benefits seen early after treatment initiation and sustained throughout the therapy.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Javed Butler et al.

Summary: This secondary analysis of the EMPEROR-Reduced trial found that empagliflozin improved the risk of cardiovascular death or heart failure hospitalization across a range of baseline health statuses. The benefits of empagliflozin in improving health status were sustained during long-term follow-up.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif et al.

Summary: In a randomized trial, the SGLT2 inhibitor dapagliflozin significantly improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF) over a 12-week period, which can lead to an enhanced quality of life for these patients.

NATURE MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

Joao Pedro Ferreira et al.

Summary: In patients with heart failure and reduced ejection fraction, the effects of empagliflozin were similar in those using or not using MRAs. Empagliflozin treatment was associated with less discontinuation of MRAs.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Heart Failure and a Preserved Ejection Fraction A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials

Milton Packer et al.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

Milton Packer et al.

Summary: Empagliflozin significantly reduced the risk of heart failure-related inpatient and outpatient events in patients with heart failure with preserved ejection fraction, including cardiovascular death, heart failure hospitalization, and urgent visits, while also decreasing total heart failure hospitalizations and intensive care admissions. Patients receiving empagliflozin may experience improved New York Heart Association functional class levels.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Scott D. Solomon et al.

CIRCULATION (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

Scott D. Solomon et al.

EUROPEAN HEART JOURNAL (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients

SD Solomon et al.

CIRCULATION (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.